C-reactive protein (CRP) Interleukin-6 (IL-6) Tumor necrosis factor (TNF) Interleukin-1b (IL-1b) Low back pain (LBP) a b s t r a c t Systemic inflammation is linked with development and persistence of many pathological pain states. Although chronic phase inflammatory responses are well reported, the acute phase has received limited attention. Here we investigated circulating pro-inflammatory cytokines and C-reactive protein (CRP), and explored their relationships with symptom severity and other factors in acute low back pain (LBP). Ninety-nine individuals within two weeks of onset of acute LBP and 55 pain-free controls completed questionnaires related to their pain (visual analogue scale, VAS) and disability, behaviour, sleep quality and psychological status. CRP, interleukin-6 (IL-6), tumor necrosis factor (TNF) and interleukin-1b (IL-1b) were measured from serum samples. Biomarkers were compared between LBP and control participants, and in a separate analysis, for those with ''high-pain" (VAS P4) and ''low-pain" (VAS <4). The relationships between biomarkers and all other variables, including other cytokines/CRP were assessed. CRP was higher in LBP than controls and in those with high-than low-pain (p < 0.01). IL-6 was higher in those with high-than low-pain (p < 0.05), but not controls. Various pain and non-pain factors were associated with each biomarker differently. These findings suggest systemic CRP and IL-6 are important contributors to inflammation in the early post-onset phase of LBP and that various factors can shape these responses.
Introduction
Development and persistence of many pain states has been linked with a systemic inflammatory response (Carp et al., 2007; Wang et al., 2008) . Attention has focused on inflammatory cytokines and mediators that play key roles in the immune response following injury or harmful stimuli (Carp et al., 2008) . Cytokines are proteins produced by numerous cells that have specific effects on the interactions and communications between immune-related cells, and play an integral role in the initiation, perpetuation and downregulation of the immune response (Zhang and An, 2007) . In addition to their role in the immune response, proinflammatory cytokines sensitise nociceptors either directly or via stimulation of the release of agents that modulate nociception both peripherally and centrally (Abbadie, 2005; Watkins and Maier, 2003) . Pro-inflammatory cytokines have also been implicated in the development of ''sickness" symptoms such as depression, anxiety, sleep disturbances and cognitive deficits (Miller et al., 2009; Strouse, 2007) . These relationships are bidirectional; peripheral pro-inflammatory cytokines can induce sickness behaviours and sickness behaviours can upregulate peripheral proinflammatory cytokines (Messay et al., 2012) .
Many chronic pain conditions are linked with elevated circulating pro-inflammatory cytokines. Elevated tumor necrosis factor (TNF) has been reported in chronic low back pain (LBP) Wang et al., 2008, interleukin-6 (IL-6) in fibromyalgia (Hernandez et al., 2010) and interleukin-1b (IL-1b) in chronic tension-type headache (Della Vedova et al., 2013) . In some cases cytokines are related to symptom severity (e.g. upper-extremity overuse disorders (Carp et al., 2007) ; mixed chronic musculoskeletal pain conditions (Koch et al., 2007) . C-reactive protein (CRP) is a reactant in the acute phases of inflammation primarily synthesised in the liver in response to IL-6 (Heikkila et al., 2007) , an effect that is enhanced by IL-1b (Kushner et al., 1995; Mackiewicz et al., 1991) and TNF (Nanri et al., 2007) . Elevated CRP has been reported in pain disorders (Carp et al., 2007; Rannou et al., 2007; Reveille, 2015; Xiao et al., 2013) and is also associated with symptom severity (Carp et al., 2007; Sturmer et al., 2005) . Although the role is unclear, CRP is an important clinical marker of inflammation (Salazar et al., 2014) , predictor of some inflammatory diseases (Nanri et al., 2007; Ridker, 2003) , and marker of treatment response (Marnell et al., 2005) .
